Overall, there are many novel autoimmune candidate targets and KDR (VEGFR2) emerges as one very promising with 36 protein structures, potent decrease in expression of CD70 and CD80 following knock out of target in activated Namalwa cells without affecting cell viability and links to both cancer and auto-immunity. This evidence concerns the gene CD80 and cancer.